Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Japan’s 1st OTC Morning-After Pill Now Available
Daiichi Sankyo Healthcare on February 2 launched NorLevo (levonorgestrel), Japan’s first over-the-counter emergency contraceptive, often referred to as a morning after pill. The product contains the same active ingredient at the same dose as ASKA Pharmaceutical’s prescription NorLevo Tablet 1.5…
To read the full story
Related Article
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
- Fuji Pharma Filed for OTC Approval of Emergency Contraceptive Last October
June 27, 2025
- ASKA Filed Switched OTC of Emergency Contraceptive Last June
May 16, 2025
- Set Deadline for Non-Prescription Pilot of Morning-After Pill: Panel Members
February 13, 2025
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
May 18, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
BUSINESS
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
- ASKA Starts PIII Trial of Drospirenone for Dysmenorrhea in Japan
November 5, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…